| Identification | Back Directory | [Name]
SKLB-1028 | [CAS]
1350544-93-2 | [Synonyms]
SKLB-1028
ruserontinib
9-isopropyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)-8-(pyridin-3-yl)-9H-purine
9-Isopropyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-(pyridin-3-yl)-9H-purine-2,8-diamine
9H-Purine-2,8-diamine, 9-(1-methylethyl)-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N8-3-pyridinyl- | [Molecular Formula]
C24H29N9 | [MDL Number]
MFCD30471083 | [MOL File]
1350544-93-2.mol | [Molecular Weight]
443.55 |
| Chemical Properties | Back Directory | [Boiling point ]
671.8±65.0 °C(Predicted) | [density ]
1.32±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
7.89±0.42(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Uses]
SKLB-??1028 is a multikinase inhibitor with exceptional activity in models of FLT3-??driven acute myeloid leukemia and considerable potency in chronic myeloid leukemia that harbors Abl mutations. | [in vivo]
Ruserontinib (SKLB1028) (5-70 mg/kg, orally once daily, 18 days) have anti-tumor effect in MV4-11 and K562 xenograft NOD-SCID models[1].
| Animal Model: | MV4-11 and K562 xenograft NOD-SCID models[1] | | Dosage: | 5, 10, 20 mg/kg,70 mg/kg | | Administration: | orally once daily, 18 days | | Result: | Prevented tumor growth at a dose of 5 mg/kg, and caused rapid and complete tumor regression in both groups of mice at a dose of 10 or 20 mg/kg.
Significantly inhibited the proliferation and induced apoptosis of MV4-11 and K562 cells at a dose of 70 mg/kg. |
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
AstaTech, Inc
|
| Tel: |
(215) 785 3197 |
| Website: |
www.astatechinc.com |
|